A review on potential of PARP inhibitors in the treatment of prostate cancer

A review on potential of PARP inhibitors in the treatment of prostate cancer

This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2022.

Бібліографічні деталі
Автор:	Islam, Saidul
Інші автори:	Sharmin, Shahana
Формат:	Дисертація
Мова:	English
Опубліковано:	Brac University 2022
Предмети:	Prostate cancer Therapeutic approaches mCRPC PARP inhibitors Olaparib Cancer > Treatment Enzyme inhibitors > Therapeutic use Cancer > Gene therapy
Онлайн доступ:	http://hdl.handle.net/10361/17308

Схожі ресурси

A review on newly approved PARP inhibitors: Talazoparib and Olaparib
за авторством: Karim, Azrin
Опубліковано: (2024)

Efficacy analysis of tyrosine kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer
за авторством: Flora, Sanzida Alam
Опубліковано: (2024)

SHP2 inhibitors: Recent advancements and potential breakthroughs in cancer therapy
за авторством: Meem, Manila
Опубліковано: (2023)

Benign Prostatic Hyperplasia & Prostate Cancer: a review on the treatment strategies
за авторством: Alam, Tahera
Опубліковано: (2024)

RIPK pathway, as a potential target, for cancer treatment - a review
за авторством: Jahan, Nusrat
Опубліковано: (2024)

Association of XRCC1 and XPD polymorphism with risk of prostate cancer in Bangladesh population
за авторством: Ahmed, Nafisa
Опубліковано: (2023)

Immunotherapy in the Management of Lung Cancer
за авторством: Tasnim, Humayra
Опубліковано: (2022)

A review on triple-negative breast cancer and its potential treatment
за авторством: Niasa, Jannatul Ferdous
Опубліковано: (2023)

Stem cells as therapeutic carrier in cancer treatment
за авторством: Anika, Mysha Yeasmin
Опубліковано: (2022)

An examination of therapeutic synergy: a comprehensive meta-analysis comparing the efficacy of TAS-102 and FOLFOX as a combination therapy for colon cancer
за авторством: Hasan, Amit
Опубліковано: (2024)

Drug repurposing: potential of Antimicrobial Drugs in Breast Cancer Treatment
за авторством: Chakraborty, Anuradha
Опубліковано: (2024)

A review on Bruton's Tyrosine Kinase inhibitors to outline the scopes of further advancements in the treatment of cancer
за авторством: Khan, Muidul Hasan
Опубліковано: (2024)

A review on potential role of cannabinoids as therapeutic agents in different types of cancer
за авторством: Roy, Hredita
Опубліковано: (2018)

Recent advances in Cancer treatment targeting autophagy and future aspects
за авторством: Emon, Kamrul Hasan
Опубліковано: (2022)

Tamoxifen: The ideal post operative hormonal therapy to demote Ductal Carcinoma in Situ
за авторством: Mirza, Maisa Tasnim
Опубліковано: (2023)

Role of toll-like receptors in cancer immunotherapy– a review
за авторством: Khan, Rezia Nowrin
Опубліковано: (2021)

In silico analysis revealed hsa-miR-19a-3p and hsa-miR-19b-3p as two potential inhibitors of EGF mRNA in Breast Cancer
за авторством: Nuha, Nabiha Tahsin
Опубліковано: (2024)

Role of statins as antagonists of SPARC in gastric cancer
за авторством: Shahmat, Rad
Опубліковано: (2019)

A review on cyclin-dependent kinase 7 (CDK7) Inhibitors as anticancer agents
за авторством: Sorno, Rubina Haque
Опубліковано: (2024)

A review of next-generation immuno-oncology agents for cancer therapy: recent dictation shifts in cancer immunotherapy
за авторством: Ratu, Tabassum
Опубліковано: (2024)

A review on bispecific antibody (blinatumomab) for the treatment of acute lymphoblastic leukemia
за авторством: Choki, Kinley
Опубліковано: (2024)

Recent developments in the Adeno-Associated Viral Gene Therapy for Non-Small Cell Lung Cancer during the past 20 years
за авторством: Razna, Amrin Islam
Опубліковано: (2019)

A comprehensive review on drug repurposing in cancer treatment
за авторством: Sarkar, Onusree
Опубліковано: (2024)

A review on RNAi technology and its therapeutic potential in Cancer
за авторством: Mahaleka, Aarshi
Опубліковано: (2024)

Prevalence and application of an evolving genome editing tool “CRISPR/Cas System” in cancer research and treatment
за авторством: Shaikat, Mahdi Mubin
Опубліковано: (2023)

Genetic innovations for breast cancer treatment : a review of gene therapy strategies and future implications
за авторством: Hasan, Sakib
Опубліковано: (2024)

Survey on patients undergoing treatments for cervical, endometrial and ovarian cancer
за авторством: Nawar, Anika
Опубліковано: (2019)

Statistics and informatics in molecular cancer research

Identification of FAP inhibitors using in silico simulation study
за авторством: Deeba, Maliha Tasnim
Опубліковано: (2018)

Targeting BRAFV600E in the treatment of CRC
за авторством: Roja, Mashwiyat Samrin
Опубліковано: (2024)

Targeted therapeutic options in the treatment of Breast Cancer
за авторством: Alam, Kazi Tasnuva
Опубліковано: (2022)

Clinical outcomes and safety comparison of gemcitabine plus cisplatin, capecitabine monotherapy, and gemcitabine plus oxaliplatin in the management of gallbladder carcinoma: a comprehensive meta-analysis
за авторством: Rahman, Sanjida
Опубліковано: (2024)

Biosimilar in lymphoma treatment
за авторством: Tanisha, Mehrin Haque
Опубліковано: (2021)

Current practice and approaches of immunotherapy in Cancer treatment
за авторством: Khondokar, Faiza
Опубліковано: (2022)

A pharmacovigilance study on FDA approved interleukin inhibitor-associated alopecia in the treatment of psoriasis
за авторством: Islam, Nahidul
Опубліковано: (2023)

A review on Single Nucleotide Polymorphism (SNPs) and their effect on cancer risk in South Asian population
за авторством: Beruni, Sajid Mahmud Al
Опубліковано: (2022)

Oncogenes: new targets in cancer treatment
за авторством: Chowdhury, Waseka Shams
Опубліковано: (2020)

Potential phytochemicals and dietary components for the prevention and treatment of skin cancer: A review
за авторством: Muntaha, Habibatul
Опубліковано: (2023)

A review of comparison on efficacy, safety and cost effectiveness of cholinesterase inhibitors, NMDA antagonists and combination therapy in the treatment of Alzheimer’s disease
за авторством: Haque, Mushfiqul
Опубліковано: (2019)

Pooled analysis of response rate and overall survival of Tyrosine Kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer
за авторством: Karim, Samia Binte
Опубліковано: (2024)